Literature DB >> 18803288

Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q.

Tae-Min Kim1, Seon-Hee Yim, Seung-Hun Shin, Hai-Dong Xu, Yu-Chae Jung, Cheol-Keun Park, Jong-Young Choi, Won-Sang Park, Mi-Seon Kwon, Heike Fiegler, Nigel P Carter, Mun-Gan Rhyu, Yeun-Jun Chung.   

Abstract

To elucidate the pathogenesis of hepatocellular carcinoma (HCC) and develop useful prognosis predictors, it is necessary to identify biologically relevant genomic alterations in HCC. In our study, we defined recurrently altered regions (RARs) common to many cases of HCCs, which may contain tumor-related genes, using whole-genome array-CGH and explored their associations with the clinicopathologic features. Gene set enrichment analysis was performed to investigate functional implication of RARs. On an average, 23.1% of the total probes were altered per case. Mean numbers of altered probes are significantly higher in high-grade, bigger and microvascular invasion (MVI) positive tumors. In total, 32 RARs (14 gains and 18 losses) were defined and 4 most frequent RARs are gains in 1q21.1-q32.1 (64.5%), 1q32.1-q44 (59.2%), 8q11.21-q24.3 (48.7%) and a loss in 17p13.3-p12 (51.3%). Through focusing on RARs, we identified genes and functional pathways likely to be involved in hepatocarcinogenesis. Among genes in the recurrently gained regions on 1q, expression of KIF14 and TPM3 was significantly increased, suggesting their oncogenic potential in HCC. Some RARs showed the significant associations with the clinical features. Especially, the recurrent loss in 9p24.2-p21.1 and gain in 8q11.21-q24.3 are associated with the high tumor grade and MVI, respectively. Functional analysis showed that cytokine receptor binding and defense response to virus pathways are significantly enriched in high grade-related RARs. Taken together, our results and the strategy of analysis will help to elucidate pathogenesis of HCC and to develop biomarkers for predicting behaviors of HCC. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18803288      PMCID: PMC2698448          DOI: 10.1002/ijc.23901

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  41 in total

1.  GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways.

Authors:  Kam D Dahlquist; Nathan Salomonis; Karen Vranizan; Steven C Lawlor; Bruce R Conklin
Journal:  Nat Genet       Date:  2002-05       Impact factor: 38.330

2.  DNA microarrays for comparative genomic hybridization based on DOP-PCR amplification of BAC and PAC clones.

Authors:  Heike Fiegler; Philippa Carr; Eleanor J Douglas; Deborah C Burford; Sarah Hunt; Carol E Scott; James Smith; David Vetrie; Patricia Gorman; Ian P M Tomlinson; Nigel P Carter
Journal:  Genes Chromosomes Cancer       Date:  2003-04       Impact factor: 5.006

3.  Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray.

Authors:  Yi Wang; Meng-Chao Wu; Jonathan S T Sham; Weigou Zhang; Wei-Qing Wu; Xin-Yuan Guan
Journal:  Cancer       Date:  2002-12-01       Impact factor: 6.860

4.  GEAR: genomic enrichment analysis of regional DNA copy number changes.

Authors:  Tae-Min Kim; Yu-Chae Jung; Mun-Gan Rhyu; Myeong Ho Jung; Yeun-Jun Chung
Journal:  Bioinformatics       Date:  2007-11-23       Impact factor: 6.937

5.  Interferon-alpha activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes.

Authors:  Svetlana Radaeva; Barbara Jaruga; Feng Hong; Won-Ho Kim; Saijun Fan; Hongbo Cai; Stephen Strom; Youhua Liu; Osama El-Assal; Bin Gao
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

Review 6.  Genes and viruses in hepatobiliary neoplasia.

Authors:  M E Reeves; R P DeMatteo
Journal:  Semin Surg Oncol       Date:  2000 Sep-Oct

7.  TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.

Authors:  Kohichiroh Yasui; Shigeki Arii; Chen Zhao; Issei Imoto; Masakazu Ueda; Hisaki Nagai; Mitsuru Emi; Johji Inazawa
Journal:  Hepatology       Date:  2002-06       Impact factor: 17.425

8.  Mapping of a minimal deleted region in human hepatocellular carcinoma to 1p36.13-p36.23 and mutational analysis of the RIZ (PRDM2) gene localized to the region.

Authors:  W Fang; Z Piao; D Simon; J C Sheu; S Huang
Journal:  Genes Chromosomes Cancer       Date:  2000-07       Impact factor: 5.006

9.  PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas.

Authors:  Hiroyuki Okamoto; Kohichiroh Yasui; Chen Zhao; Shigeki Arii; Johji Inazawa
Journal:  Hepatology       Date:  2003-11       Impact factor: 17.425

10.  Evidence for another tumor suppressor gene at 17p13.3 distal to TP53 in hepatocellular carcinoma.

Authors:  Xin Yuan Guan; Jonathan S T Sham; Lai Shan Tai; Yan Fang; Hong Li; Qiwan Liang
Journal:  Cancer Genet Cytogenet       Date:  2003-01-01
View more
  40 in total

1.  A potential oncogenic role of the commonly observed E2F5 overexpression in hepatocellular carcinoma.

Authors:  Yuzhu Jiang; Seon-Hee Yim; Hai-Dong Xu; Seung-Hyun Jung; So Young Yang; Hae-Jin Hu; Chan-Kwon Jung; Yeun-Jun Chung
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

2.  Integrated analysis of copy number alteration and RNA expression profiles of cancer using a high-resolution whole-genome oligonucleotide array.

Authors:  Seung-Hyun Jung; Seung-Hun Shin; Seon-Hee Yim; Hye-Sun Choi; Sug-Hyung Lee; Yeun-Jun Chung
Journal:  Exp Mol Med       Date:  2009-07-31       Impact factor: 8.718

3.  Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients.

Authors:  Peiyong Jiang; Carol W M Chan; K C Allen Chan; Suk Hang Cheng; John Wong; Vincent Wai-Sun Wong; Grace L H Wong; Stephen L Chan; Tony S K Mok; Henry L Y Chan; Paul B S Lai; Rossa W K Chiu; Y M Dennis Lo
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

4.  Common variants at the promoter region of the APOM confer a risk of rheumatoid arthritis.

Authors:  Hae Jin Hu; Eun Heui Jin; Seon Hee Yim; So Young Yang; Seung Hyun Jung; Seung Hun Shin; Wan Uk Kim; Seung Cheol Shim; Tai Gyu Kim; Yeun Jun Chung
Journal:  Exp Mol Med       Date:  2011-11-30       Impact factor: 8.718

5.  Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma.

Authors:  Nicola Personeni; Lorenza Rimassa; Tiziana Pressiani; Annarita Destro; Claudia Ligorio; Maria Chiara Tronconi; Silvia Bozzarelli; Carlo Carnaghi; Luca Di Tommaso; Laura Giordano; Massimo Roncalli; Armando Santoro
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-09       Impact factor: 4.553

6.  Laminin-binding integrin gene copy number alterations in distinct epithelial-type cancers.

Authors:  William L Harryman; Erika Pond; Parminder Singh; Andrew S Little; Jennifer M Eschbacher; Raymond B Nagle; Anne E Cress
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

Review 7.  Iodothyronine deiodinases and cancer.

Authors:  A Piekiełko-Witkowska; A Nauman
Journal:  J Endocrinol Invest       Date:  2011-05-27       Impact factor: 4.256

8.  Genomic losses at 5q13.2 and 8p23.1 in dysplastic hepatocytes are common events in hepatitis B virus-related hepatocellular carcinoma.

Authors:  Zhang Zhao; Guang-Yong Chen; Jiang Long; Hai Li; Jian Huang
Journal:  Oncol Lett       Date:  2015-04-23       Impact factor: 2.967

9.  High resolution genome-wide analysis of chromosomal alterations in Burkitt's lymphoma.

Authors:  Saloua Toujani; Philippe Dessen; Nathalie Ithzar; Gisèle Danglot; Catherine Richon; Yegor Vassetzky; Thomas Robert; Vladimir Lazar; Jacques Bosq; Lydie Da Costa; Christine Pérot; Vincent Ribrag; Catherine Patte; Jöelle Wiels; Alain Bernheim
Journal:  PLoS One       Date:  2009-09-17       Impact factor: 3.240

10.  Sox17 inhibits hepatocellular carcinoma progression by downregulation of KIF14 expression.

Authors:  Tao Yang; Xiao-Na Li; Li Li; Qi-Mei Wu; Peng-Zhi Gao; Hong-Lei Wang; Wei Zhao
Journal:  Tumour Biol       Date:  2014-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.